Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.
Zanghì A, Gallo A, Avolio C, Capuano R, Lucchini M, Petracca M, Bonavita S, Lanzillo R, Ferraro D, Curti E, Buccafusca M, Callari G, Barone S, Pontillo G, Abbadessa G, Di Francescantonio V, Signoriello E, Lus G, Sola P, Granella F, Valentino P, Mirabella M, Patti F, D'Amico E.
Zanghì A, et al. Among authors: capuano r.
Neurotherapeutics. 2021 Apr;18(2):1166-1174. doi: 10.1007/s13311-021-01037-2. Epub 2021 Apr 12.
Neurotherapeutics. 2021.
PMID: 33844155
Free PMC article.
Clinical Trial.